

Chloroquine Phosphate Suspension 15 mg/mL - Formulation 2

Ingredients:

Chloroquine phosphate powder	1.8 g
SyrSpend SF PH4	QSAD: 120 mL

Preparation Details:

1. Weigh out powder and add to mortar and pestle.
2. Triturate powder to a fine powder.
3. Levigate with a small amount of base solution to form a paste.
4. Add base solution in increasing amounts while mixing thoroughly.
5. Transfer contents of the mortar to a graduated cylinder.
6. Rinse the mortar and pestle with base solution and pour into graduated cylinder.
7. Add base solution to the graduated cylinder to achieve the total volume indicated above.
8. Transfer contents of the graduated cylinder into an appropriate size amber bottle.
9. Shake well to mix.

Storage Conditions: Refrigerate or Room Temp

Special Instructions: Chloroquine phosphate 15 mg/mL = Chloroquine base 9 mg/mL.
Chloroquine phosphate 500 mg = chloroquine base 300 mg.

Stability-indicating Study: Yes

Equipment and Supplies: Powder containment hood, pharmaceutical analytical scale, mortar and pestle, graduated cylinder

Container Closure: Low-actinic, light-resistant prescription bottle

Label Requirements: Extemporaneously compounded preparation. For oral use only. Store in room temperature or refrigerator. Shake well before use.

Quality-control Procedure: Visual inspection for physical appearance of solution and container closure integrity (no leakage, cracks in container or improper seals)

Manufacturer: Chloroquine phosphate powder, SyrSpend SF PH4 (Fagron)

Stable for 90 days

Reference

1. Ferreira AO, Polonini HC, Silva SL, et al. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim, and zonisamide in SyrSpend SF PH4 oral suspensions. *J Pharm Biomed Anal.* 2016;188:105-112.

Review Date: 9/22/2019

The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product. Because of ongoing research and improvements in technology, the information and its applications contained in this text are constantly evolving and are subject to the professional judgment and interpretation of the practitioner due to the uniqueness of a clinical situation. The editors and ASHP have made reasonable efforts to ensure the accuracy and appropriateness of the information presented in this document. However, any user of this information is advised that the editors and ASHP are not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the document in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this document and specifically disclaims any liability to any party for the accuracy and/or completeness of the material or for any damages arising out of the use or non-use of any of the information contained in this document.